Gerresheimer’s decision to concentrate on the pharmaceutical and life science sectors and sell-off non-core divisions appears to be paying dividends judging by a 14 per cent jump in third quarter operating profit.
Albany Molecular Research (AMRI) has slipped again in the fourth
quarter of 2006 recording an operating loss of $2.5m (€1.9m) - six
per cent worse than the same quarter the previous year - despite
encouraging revenue growth in its...